JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Norbert Zimmermann
Joachim Winter
Emmeran Gams
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimmermann, N.
Right arrow Articles by Hohlfeld, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimmermann, N.
Right arrow Articles by Hohlfeld, T.
Related Collections
Right arrow Cardiac - pharmacology

J Thorac Cardiovasc Surg 2006;131:1392-1393
© 2006 The American Association for Thoracic Surgery

Brief Communication

Platelet inhibition by aspirin after aortic valve replacement

Norbert Zimmermann, MD a , * , Timothée Roussiekan, MD b , Joachim Winter, MD c , Muhamed Kurt, MD c , Emmeran Gams, MD c , Folker Wenzel, MD d , Thomas Hohlfeld, MD b

a Federal Institute for Drugs and Medical Devices, Bonn, Germany
b Departments of Pharmacology and Clinical Pharmacology, Heinrich Heine—University Düsseldorf, Germany
c Departments of Thoracic and Cardiovascular Surgery, Heinrich Heine—University Düsseldorf, Germany
d Departments of Hemostasis and Transfusion Medicine, Heinrich Heine—University Düsseldorf, Germany.

Received for publication January 3, 2006; accepted for publication January 24, 2006.

* Address for reprints: Norbert Zimmermann, MD, Federal Institute for Drugs and Medical Devices, Kurt Georg Kiesinger Allee, D-53175 Bonn, Germany. (Email: nzimmermann@bfarm.de).

The first 20% of the full text of this article appears below.

In spite of antithrombotic therapy, the thromboembolic risk after aortic valve replacement appears to be high for the first 3 months after surgical intervention (3.6%), especially during the first 10 postoperative days. 1 Go

We have previously shown that 100 mg of aspirin, a dose that is effective for early antithrombotic treatment after coronary artery bypass grafting (CABG), did not sufficiently inhibit platelet function in patients subjected to CABG, indicating a remarkable resistance against the antiplatelet effect of aspirin in the early postoperative period. 2 Go

The present work determined platelet function early after aortic valve replacement and examined whether the antiplatelet effect of aspirin, based on the inhibition of platelet thromboxane production, is impaired in the early postoperative period.

Methods

Subjects and drug administration
This study was conducted in agreement with the Declaration of Helsinki and was approved by the institutional ethics committee. Fifteen consecutive patients were included who underwent an elective aortic valve replacement with bileaflet mechanical prostheses (St Jude Medical). Informed consent was obtained from each participant. Drugs affecting hemostasis (including aspirin) had been terminated at least 7 days before surgical intervention. Antithrombotic . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
N. Zimmermann, E. Gams, and T. Hohlfeld
Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent
Eur J Cardiothorac Surg, July 1, 2008; 34(1): 93 - 108.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.